FDA's Animal Testing Alternatives: Year 1 Progress

The FDA announced it has met its Year 1 milestones under its roadmap to reduce animal testing in drug development — a roadmap it published in April 2024. On the surface, this reads like a bureaucratic progress report. I think it's actually a signal that the regulatory ground under new drug applications is shifting faster than most sponsors realize.

If you're running preclinical programs right now, this is worth understanding beyond the press release.

What the FDA Actually Announced

According to the FDA's official press announcement, the agency has successfully launched several key initiatives since publishing its alternative methods roadmap in April 2024. The Year 1 goals centered on expanding the use of New Approach Methodologies (NAMs) — a broad category that includes organ-on-a-chip systems, in vitro cell models, computational toxicology tools, and AI-driven predictive modeling — as alternatives or supplements to traditional animal studies.

The specific milestones FDA cited include standing up internal centers of expertise for NAMs review, publishing new guidance documents on when and how NAMs data can support IND and NDA submissions, and initiating pilot programs with sponsors who want to substitute animal studies with alternative methods.

This didn't happen in a vacuum. The FDA Modernization Act 2.0, signed into law in December 2022, formally removed the statutory requirement that drugs must be tested in animals before human trials. That legislation set the stage; the April 2024 roadmap was FDA's operational response; and these Year 1 results are the first concrete evidence the agency is actually building the infrastructure to make NAMs a viable regulatory pathway — not just a stated aspiration.

Why This Is Moving Faster Than People Expected

I'll be honest — when the Modernization Act 2.0 passed, I expected the usual pattern: legislation arrives, FDA acknowledges it, guidance trickles out over five to seven years, and industry waits. That's been the rhythm on plenty of other regulatory shifts.

This one appears different, and I think there are a few reasons.

First, the science has genuinely matured. Organ-on-a-chip technology has progressed from a research curiosity to something that can produce reproducible, auditable data. The gap between "interesting platform" and "data package FDA will actually review" has closed substantially. According to a 2023 report from the National Academies of Sciences, Engineering, and Medicine, over 40% of drug failures in clinical trials are attributable to toxicity problems that existing animal models failed to predict — which gives FDA a genuine scientific argument for exploring alternatives, not just a political one.

Second, the agency has external pressure from both directions. The pharmaceutical industry wants faster, cheaper preclinical programs. Animal welfare advocates want meaningful reduction in animal use. That unusual alignment of interests tends to produce faster movement than situations where industry and advocacy groups are pulling against each other.

Third, FDA Commissioner leadership has publicly committed to this initiative by name, which matters for institutional momentum. Programs that live at the Commissioner level tend to survive budget cycles and reorganizations better than programs housed in individual centers.

The Current State of NAMs Acceptance: A Practical Overview

Here's where I want to be precise, because there's genuine risk in over-reading the Year 1 announcement. FDA meeting its internal milestones is not the same as FDA routinely accepting NAMs data in place of animal studies. The pathway exists; it is not yet routine.

The table tells the real story. For most sponsors pursuing an IND today, animal studies remain the backbone of your enabling toxicology package. What has changed is that FDA is now actively creating the infrastructure to accept NAMs data alongside — and in some cases instead of — specific animal studies. The "instead of" piece is still narrow. The "alongside" piece is where I'd focus attention now.

What This Means for Your Preclinical Strategy

In my view, there are three practical implications worth thinking through if you're managing drug development programs.

First, early FDA engagement just became more valuable. The pilot program FDA launched as part of Year 1 is essentially a structured conversation channel for sponsors who want to explore NAMs-based submissions. If you're in preclinical development on a molecule where the standard animal package feels like a poor fit — biologics with no good animal model, pediatric formulations, drugs with significant species-specific metabolism — this is the moment to request a pre-IND meeting and put NAMs on the agenda explicitly. FDA is more receptive to that conversation now than at any prior point.

Second, your IND-enabling strategy may have more flexibility than your CRO is telling you. Contract research organizations have built their business models around established animal study packages. They're often not the right source of advice on when NAMs might be acceptable substitutes, because their incentive runs toward the studies they're equipped to run. I'd suggest having a parallel conversation with a regulatory consultant who has current experience with NAMs submissions before locking your preclinical plan.

Third, document your scientific rationale for every choice you make. Whether you use animal studies, NAMs, or a hybrid approach, FDA's emerging framework emphasizes that sponsors must justify their methodological choices with scientific reasoning. "We did it this way because it's what we always do" is becoming a weaker position. "We selected this method because it provides the most predictive data for this compound class" is the framing FDA wants to see.

The Honest Limits of Year 1 Progress

I want to be fair to the complexity here. Meeting internal milestones — standing up review teams, publishing guidance documents, launching pilot programs — is real progress, but it's infrastructure-building, not proof of outcome.

The harder question is whether NAMs data, when submitted, is actually being integrated into FDA review decisions in a way that reduces animal study requirements for sponsors. That data will emerge over the next two to three years as pilot programs conclude and submission patterns become visible. For now, we're watching FDA build the runway. We haven't seen many planes land yet.

There's also a GLP question that hasn't been fully resolved. Most IND-enabling toxicology studies must be conducted under Good Laboratory Practice regulations (21 CFR Part 58). Many NAMs platforms are not yet GLP-validated in a way FDA has formally accepted. Until that gap closes — either through FDA guidance that establishes GLP equivalence standards for NAMs, or through formal qualification of specific platforms — sponsors face real uncertainty about what evidentiary weight their NAMs data will carry.

A 2024 survey conducted by the Alliance for Advancing Biomedical Research found that 67% of pharmaceutical sponsors said regulatory uncertainty was the primary barrier to adopting NAMs in their preclinical programs — ahead of cost, technical capability, and scientific uncertainty. FDA's Year 1 progress is aimed directly at that barrier, which is the right target.

What Good Regulatory Strategy Looks Like Right Now

At Certify Consulting, I've spent the better part of eight-plus years helping sponsors navigate exactly this kind of regulatory transition — moments when the rules are changing but the new rules aren't fully written yet. In my experience, the sponsors who benefit most from these transitions are the ones who engage early rather than waiting for everything to be settled.

Settled guidance is useful. It's also usually too late to give you a competitive advantage, because everyone has access to it at the same moment.

Here's what I'd suggest thinking about practically:

If you have molecules in early discovery, build NAMs data generation into your preclinical plan now — not as a replacement for animal studies, but as parallel data that strengthens your scientific package and positions you to take advantage of FDA's evolving acceptance criteria.

If you have molecules approaching IND-enabling studies, request a pre-IND meeting and ask FDA directly how they'd view a hybrid package for your specific compound and indication. The answer will tell you more than any guidance document.

If you're post-IND and thinking about supplemental applications or line extensions, watch the guidance FDA publishes through the rest of 2025 and into 2026. The agency has signaled that additional guidance on NAMs acceptance criteria for specific study types is coming. That guidance could change the cost structure of your supplemental programs meaningfully.

One declarative statement worth carrying forward: The FDA's Year 1 milestone achievement is the clearest signal yet that NAMs are moving from regulatory exception to regulatory option — and sponsors who understand that distinction will be better positioned than those who don't.

What Comes Next: FDA's Stated Year 2 Priorities

Based on the agency's public statements and the structure of the April 2024 roadmap, Year 2 priorities are expected to include expanding the NAMs pilot program, publishing additional guidance on specific study types where alternatives are accepted, and establishing a more formal qualification pathway for NAMs platforms. FDA has also indicated it intends to work with ICH — the International Council for Harmonisation — to build international alignment on NAMs acceptance, which matters considerably for sponsors running global programs.

That international dimension is worth watching. If FDA and EMA develop aligned NAMs acceptance criteria, the regulatory burden reduction for global drug development programs could be substantial. Right now, a sponsor who wants to use NAMs data in an EU submission faces a different set of questions than in a US submission, which often means running parallel programs anyway. Harmonization would change that calculus.

The regulatory infrastructure being built right now will define how drugs are developed for the next two decades. That's not an overstatement — it's what happens when a foundational assumption of preclinical development (animals as the primary safety model) begins to share space with alternatives that carry genuine scientific credibility.

Expert Perspective: What I Tell My Clients

When clients ask me how to respond to FDA's NAMs initiative, I give them a version of the same answer: don't restructure your current preclinical programs around NAMs unless you have a specific scientific or regulatory reason to do so. But do start learning the landscape, engaging FDA earlier, and making sure your regulatory strategy has room to adapt.

The sponsors who will regret this transition are the ones who ignored it until the guidance was final — and then found themselves three years behind on validation studies, platform selection, and the internal expertise to support NAMs submissions. That's a slow-moving risk, but it's real.

If you want to think through how FDA's evolving NAMs framework intersects with your specific drug development program, that's exactly the kind of strategic question we work through at Certify Consulting. With 200+ clients served and a track record of 100% first-time audit pass rates, we've helped sponsors navigate regulatory transitions before the path was fully paved — and that's precisely when the guidance matters most.

You might also find it useful to review how FDA pre-IND meeting strategy affects your IND submission timeline — the principles there apply directly to NAMs-related pre-IND conversations.

Last updated: 2026-05-01